Diabetic Cardiomyopathy

Diabetic Cardiomyopathy: Diagonostic Value of 2D and 3D Left Ventricular Strains in Echocardiography in Type 2 Diabetic Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04593173

Acronym

CarDiab

Enrollment

Registered

2020-10-19

Start date

2020-10-01

Completion date

2021-11-01

Last updated

2021-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Cardiomyopathies

Keywords

Diabetes, Cardiomyopathy, Diabetic Cardiomyopathies, Type 2 diabetes, Echocardiography, Left ventricle, strain 2D and 3D

Brief summary

Diabetes represents one of the 10 leading causes of death in the world and concerns 5% of the French population (\> 3.3 million patients). About 30% of diabetic patients will develop heart failure. The specific and early identification of diabetic cardiomyopathy at a subclinical stage (asymptomatic patients with normal LVEF) will thus make it possible to predict the risk of the onset of heart failure and to strengthen their monitoring and further adapt their treatment.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patient (≥18 years old) * Type 2 diabetic and hypertensive subjects, cardiac asymptomatic, without myocardial ischemia documented by Dobutamine stress ultrasound (ESD), having at least 1 additional CV risk factor among: dyslipidemia, active or stopped smoking for less than 3 years, family history (1st degree relationship) of major CV accident before age 60, obliterating arteriopathy of the lower limbs and / or carotid atheroma, or proteinuria. * Subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research.

Exclusion criteria

* Patient who expressed his opposition to participating in the study * Valvular heart disease (moderate to severe valve disease), hypertrophic or dilated (MVGi\> 95 g / m2 in women and MVGi\> 115 g / m2 in men), chronic pulmonary; * History of cardiotoxic chemotherapy; * Subject under legal protection, under guardianship or under guardianship.

Design outcomes

Primary

Measure	Time frame
Analysis of Value of 2D and 3D Left Ventricular Strains in Echocardiography in Type 2 of diabetic Patients	The files analysed retrospectily from April 15, 2015 to April 30, 2019 will be examined]

Countries

France

Contacts

Primary ContactSamy TALHA, MD

samy.talha@chru-strasbourg.fr33 3 69 55 13 68

Backup ContactSaïd CHAYER, PhD, HDR

said.chayer@chru-strasbourg.fr33 3 88 11 66 90

Outcome results